We have been informed by the company, Janssen, that it has decided to withdraw its marketing authorisation application for sirukumab. Consequently, we have suspended this appraisal.
Status
|
Suspended
|
Decision
|
Selected
|
Process |
STA pre-2018
|
ID number |
1002
|
Project Team
Email enquiries
Stakeholders
Companies sponsors |
Janssen (sirukumab) |
Others |
Department of Health |
|
NHS England |
|
Welsh Government |
Patient carer groups |
Arthritis Action |
|
National Rheumatoid Arthritis Society |
Professional groups |
British Society for Rheumatology |
|
Primary Care Rheumatology Society |
|
Royal College of Physicians |
|
UK Clinical Pharmacy Association |
Comparator companies |
AbbVie |
|
Accord Healthcare - (CAU not returned, not participating) |
|
Amdipharm Mercury - (CAU not returned, not participating) |
|
Biogen |
|
Bristol-Myers Squibb |
|
Concordia international - (CAU not returned, not participating) |
|
Eli Lilly |
|
Hameln pharmaceuticals - (CAU not returned, not participating) |
|
Hospira - (CAU not returned, not participating) |
|
medac - (CAU not returned, not participating) |
|
Merck Sharp & Dohme |
|
Napp |
|
Nordic Pharma - (CAU not returned, not participating) |
|
Orion Pharma - (CAU not returned, not participating) |
|
Pfizer |
|
Roche |
|
Rosemont Pharmaceuticals - (CAU not returned, not participating) |
|
Sandoz - (CAU not returned, not participating) |
|
UCB Pharma Limited |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Welsh Health Specialised Services Committee |